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Dear Editor,
A 36-year-old woman (gravida 1, para 0) at 9 weeks of
gestation presented with vaginal bleeding and a non-viable
fetus. Medical abortion was performed. Histologic exami-
nation showed normal product of gestation. However,
vaginal bleeding persisted. During dilatation and curettage,
a 1 cm plaque-like lesion at the posterior cervical lip was
found. The biopsy showed an atypical mononuclear cel-
lular infiltrate intermixed with eosinophil precursors
(Fig. 1a). These neoplastic cells were medium sized, with a
high nuclear/cytoplasmic ratio and fine chromatin pattern,
consistent morphologically with blasts. Immunohisto-
chemical staining showed that the blast cells were positive
for CD45 (leucocyte common antigen) (Fig. 1b) and the
myeloid marker myeloperoxidase (Fig. 1c), but were neg-
ative for CD34 and CD117. The overall features were
consistent with myeloid sarcoma. The blood count, bone
marrow aspirate, and karyotype were normal. A positron
emission tomography–computed tomography (PET–CT)
showed a 3.3 9 1.7 cm lesion at the uterine cervix, with
standard uptake value maximum (SUVmax) of 7.4 (Fig. 1d).
Another hypermetabolic focus (SUVmax 3.0) was noted at
the left pelvic cavity, compatible with disease involvement.
She was treated with a standard induction regimen for
acute myeloid leukemia (AML) (cytarabine: 7 days; dau-
norubicin: 3 days). After 3 weeks, a reassessment PET–CT
showed reduction of the cervical lesion to 2.5 9 1.3 cm
with an SUVmax of 3.2 (Fig. 1e), consistent with partial
response. She was treated with six further cycles of con-
solidation chemotherapy (etoposide: 5 days; daunorubicin:
2 days for two cycles; high dose cytarabine for four
cycles). A reassessment PET–CT then showed complete
response. The patient has remained in complete remission
16 months after diagnosis.
Myeloid sarcoma is rare, characterized by the myelo-
blasts presenting as tumor masses at extramedullary sites
[1]. It may occur de novo, concurrently with AML or as
blastic transformation of myelodysplastic syndrome or
myeloproliferative neoplasm [2]. Frequent sites include:
the skin, lymph nodes, mediastinum, gastrointestinal tract,
bones, and testis [1, 2]. Myeloid sarcoma in the gyneco-
logical tract is very unusual, ovary and uterine cervix being
involved in equal frequencies [3]. Around two-third of the
cases had an antecedent myeloid neoplasms or concurrent
AML [3–5]. Cervical myeloid sarcoma almost invariably
presented as a mass lesion showing extensive tissue infil-
tration, manifesting as abdominal pain and vaginal bleed-
ing [3–5].
Our case was special in several aspects. The disease was
de novo. Interestingly, it presented as a missed abortion, an
association not hitherto reported. Although examination
showed a small plague, PET–CT revealed more extensive
involvement, suggesting that the myeloid sarcoma might
be causally related to abortion. PET–CT also showed
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involvement outside the uterus, so that it was instrumental
in delineating the disease extent. As cervical carcinoma is
far more common, and clinical presentation is similar,
careful histopathologic evaluation, and awareness of the
possibility of myeloid malignancies are required for the
diagnosis of myeloid sarcoma.
Fig. 1 Myeloid sarcoma of the uterine cervix. a Biopsy showing
medium-sized neoplastic cells intermixed with eosinophil precursors
(H & E). b Neoplastic cells expressed CD45 (leucocyte common
antigen) (immunoperoxidase). c Neoplastic cells expressed
myeloperoxidase (immunoperoxidase). d Positron emission tomogra-
phy, showing a hypermetabolic lesion (arrow) at the uterine cervix.
e Post-treatment scan, showing diminution of the size and metabolic
activity of the lesion
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The prognosis of cervical myeloid sarcoma appears
poor, with survival in \20 % of the cases [3, 4]. The
favorable outcome of our case might be related to early
diagnosis, further underlining the importance of recogni-
tion of this pathology in the uterine cervix.
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